CMK389

Status
Phase 2
Condition
Sarcoidosis ILD
Intervention Type
Intravenous (IV) Injection
Funder Type
Industry

Drug Details

CMK389 is an IL-18 Inhibitor.

Study Purpose

The purpose of this proof of concept study is to determine whether CMK389 displays the safety and efficacy profile to support further development in chronic pulmonary sarcoidosis.

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >